G&S Capital’s Tandem Diabetes Care TNDM Stock Holding History

G&S Capital’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,227	Closed	-$486K	–	121
2021 Q4	$486K	Buy	+3,227	New	+$436K	0.24%	88

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

G&S Capital's TNDM Position: Q1 2022 in Review

G&S Capital sold out of Tandem Diabetes Care (TNDM) in Q1 2022, closing a stake of 3,227 shares — an estimated $486K sold.

G&S Capital first reported a position in TNDM in Q4 2021 and held it in 1 quarter. The position peaked at $486K in Q4 2021. 379 funds tracked by Wall St. Rank hold TNDM as of Q1 2022.

G&S Capital reported no remaining Tandem Diabetes Care position as of Q1 2022 after selling out during the quarter.
G&S Capital sold 3,227 Tandem Diabetes Care shares in Q1 2022, an estimated $486K.
G&S Capital first reported a position in Tandem Diabetes Care in Q4 2021 and held it in 1 quarter.
G&S Capital's Tandem Diabetes Care position peaked at $486K in Q4 2021.
379 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2022.

Based on G&S Capital's 13F filing for Q1 2022, filed 15 Apr 2022.